NCT00664170View on ClinicalTrials.gov

A Bioequivalence Study of Docetaxel for Injectable Emulsion (ANX-514) in Patients With Advanced Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

April 30, 2008

Primary Completion Date

April 30, 2009

Study Completion Date

April 30, 2009

Conditions
Advanced Cancer
Interventions
DRUG

ANX-514

75 mg/m\^2

DRUG

docetaxel

75 mg/m\^2

Trial Locations (13)

1122

Marcelo T de Alvear, Buenos Aires

4000

Centro Medico San Roque, San Miguel de Tucumán

4146

Hospital Regional de Concepcion, Concepción

4400

Hospital Privado Santa Clara de Asis, Salta

5500

Centro Oncologico de Integracion Regional, Mendoza

10167

Tallinn Cancer Clinic, Tallinn

35661

Northwest Alabama Cancer Center, Muscle Shoals

45042

Signal Point Hematology/Oncology Inc., Middletown

51003

Tartu University Hospital, Clinic of Hematology and Oncology, Tartu

92093

UCSD Moores Cancer Center, La Jolla

Unknown

Hospital Universitario Austral, Buenos Aires

CP 2000

Centro Oncologico de Rosario, Rosario

S3000FFU

Isis Centro Especializado, Santa Fe

Sponsors
All Listed Sponsors
lead

Mast Therapeutics, Inc.

INDUSTRY

NCT00664170 - A Bioequivalence Study of Docetaxel for Injectable Emulsion (ANX-514) in Patients With Advanced Cancer | Biotech Hunter | Biotech Hunter